Publications by authors named "P Metrakos"
Introduction: Approximately 50% of patients diagnosed with colorectal cancer develop colorectal cancer liver metastases (CRLM). Although curative intent liver resection provides 5-year survival of 40-50%, up to 70% of patients develop recurrence of CRLM. Detection of minimal residual disease (MRD) is essential for timely, optimized treatment.
View Article and Find Full Text PDFIntroduction: Colorectal cancer liver metastasis (CRCLM) remains a lethal diagnosis, with an overall 5-year survival rate of 5-10%. Two distinct histopathological growth patterns (HGPs) of CRCLM are known to have significantly differing rates of patient survival and response to treatment. We set out to review the results of 275 patients who underwent liver resection for CRCLM at the McGill University Health Center (MUHC) and analyze their clinical outcome, mutational burden, and pattern of cancer progression in light of their HGPs, and to consider their potential effect on surgical decision making.
View Article and Find Full Text PDFArticle Synopsis
- Tranexamic acid is known to reduce bleeding and blood transfusions in various surgeries, but its effectiveness for patients undergoing liver resection due to cancer is uncertain.
- A multicenter randomized clinical trial involving 1384 patients was conducted to see if tranexamic acid decreases the need for red blood cell transfusions within 7 days after liver surgery.
- The results showed no significant difference in transfusion rates or blood loss between the tranexamic acid group and the placebo group, and those who received tranexamic acid experienced more complications.
This review explores the intricacies of evaluating cirrhotic patients for liver resection while exploring how to extend surgical intervention to those typically excluded by the Barcelona Clinic Liver Cancer (BCLC) criteria guidelines by focusing on the need for robust preoperative assessment and innovative surgical strategies. Cirrhosis presents unique challenges and complicates liver resection due to the altered physiology of the liver, portal hypertension, and liver decompensation. The primary objective of this review is to discuss the current approaches in assessing the suitability of cirrhotic patients for liver resection and aims to identify which patients outside of the BCLC criteria can safely undergo liver resection by highlighting emerging strategies that can improve surgical safety and outcomes.
View Article and Find Full Text PDFArticle Synopsis
- The study looked at a protein called TSPO that helps move cholesterol in mitochondria, and Atriol is a substance that can stop TSPO from binding to cholesterol.
- Researchers found that Atriol can help improve a liver disease called MASH by fixing mitochondrial function and reducing inflammation.
- In tests on rats with MASH, Atriol helped reduce fat buildup, inflammation, and other harmful effects, showing it might be a helpful treatment for this liver condition.